1996 - Fellow of the American Association for the Advancement of Science (AAAS)
His primary areas of study are Cancer research, Internal medicine, Pathology, Oncology and Medulloblastoma. His Cancer research research integrates issues from Wnt signaling pathway, Signal transduction, Mutation, Molecular biology and Tumor suppressor gene. Torsten Pietsch studied Internal medicine and Surgery that intersect with O-6-methylguanine-DNA methyltransferase.
His Pathology research includes elements of Neuropil and Gene expression, DNA methylation. His study in Oncology is interdisciplinary in nature, drawing from both Glioblastoma, Cancer, Cohort and Glioma. His studies in Medulloblastoma integrate themes in fields like Clinical trial, Bioinformatics, Gene expression profiling, Immunology and Meta-analysis.
His primary scientific interests are in Internal medicine, Pathology, Cancer research, Oncology and Medulloblastoma. His Internal medicine study integrates concerns from other disciplines, such as Surgery and Glioma. His Central nervous system research extends to the thematically linked field of Pathology.
His Cancer research research incorporates elements of Mutation, Methylation, Gene, DNA methylation and Tumor suppressor gene. His research integrates issues of Cancer, Clinical trial, Cohort and Hazard ratio in his study of Oncology. His research brings together the fields of Bioinformatics and Medulloblastoma.
Internal medicine, Cancer research, Oncology, Ependymoma and Chemotherapy are his primary areas of study. His Internal medicine study combines topics in areas such as Gastroenterology and Medulloblastoma. The concepts of his Medulloblastoma study are interwoven with issues in Retrospective cohort study and Non metastatic.
Torsten Pietsch combines subjects such as Methylation and DNA with his study of Cancer research. His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Clinical trial, Proportional hazards model and Hazard ratio. His Ependymoma research is included under the broader classification of Pathology.
Torsten Pietsch focuses on Cancer research, Internal medicine, Oncology, Pathology and Ependymoma. His work in the fields of Cancer research, such as Glioblastoma, overlaps with other areas such as Ceritinib. His work deals with themes such as Target expression and Glioma, which intersect with Internal medicine.
His biological study spans a wide range of topics, including Temozolomide, Recurrent glioblastoma, Monoclonal antibody and Hazard ratio. His Pathology study combines topics from a wide range of disciplines, such as Tumor progression and Neuroepithelial cell. His work in DNA methylation tackles topics such as Germline which are related to areas like Medulloblastoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.
Walter Stummer;Hanns-Jürgen Reulen;Thomas Meinel;Uwe Pichlmeier.
Negative Feedback Loop of Wnt Signaling through Upregulation of Conductin/Axin2 in Colorectal and Liver Tumors
Barbara Lustig;Boris Jerchow;Martin Sachs;Sigrid Weiler.
Molecular and Cellular Biology (2002)
Long-term survival with glioblastoma multiforme
Dietmar Krex;Barbara Klink;Christian Hartmann;Andreas Von Deimling.
DNA methylation-based classification of central nervous system tumours
David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick;Christian Hartmann;Corinna Engel;Mandy Stoffels.
Journal of Clinical Oncology (2009)
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
Marcel Kool;Andrey Korshunov;Marc Remke;Marc Remke;David T.W. Jones.
Acta Neuropathologica (2012)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas
Christian Hartmann;Christian Hartmann;Bettina Hentschel;Wolfgang Wick;Wolfgang Wick;David Capper.
Acta Neuropathologica (2010)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge.
Lancet Oncology (2014)
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone
Stefan Rutkowski;Udo Bode;Frank Deinlein;Holger Ottensmeier.
The New England Journal of Medicine (2005)
Treatment of brain tumors
Arnold C. Paulino;Bin S. Teh;Michelle Sadeh;Lynn Ashby.
The New England Journal of Medicine (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: